Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015225 | 1.00 | KMT2A (0.48) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL8523068 | 0.81 | KMT2A (0.57) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4475825 | 0.78 | SLC6A3 (0.51) | KMT2AMAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL8210768 | 0.78 | PRSS1 (0.61) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL9698622 | 0.76 | KMT2A (0.58) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL9698668 | 0.76 | KMT2A (0.58) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL9698628 | 0.76 | KMT2A (0.58) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL547858 | 0.76 | KMT2A (0.54) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL14612371 | 0.76 | LMNA (0.55) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL6721979 | 0.76 | ALDH1A1 (0.56) | KMT2AMAPTTDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | claimed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | claimed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | claimed |
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | disclosed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | NR1H4, MMP8, NR1I2 | KMT2A 4271/4885MAPT 1794/4885TDP1 4443/4885 |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | KMT2A 4271/4885MAPT 1794/4885TDP1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.